Online inquiry

IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ623MR)

This product GTTS-WQ623MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL9 gene. The antibody can be applied in Asthma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000590.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3578
UniProt ID P15248
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ623MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3703MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ8021MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ6696MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ7792MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ1631MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ4745MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ7658MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ15830MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW